Northwestern Mutual Wealth Management Co. Buys 32,392 Shares of DexCom, Inc. $DXCM

Northwestern Mutual Wealth Management Co. raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 209.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 47,826 shares of the medical device company’s stock after acquiring an additional 32,392 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in DexCom were worth $3,174,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. CVA Family Office LLC lifted its stake in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the period. ORG Partners LLC lifted its stake in DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 281 shares during the period. Spire Wealth Management lifted its stake in DexCom by 113.8% during the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after acquiring an additional 305 shares during the period. Aventura Private Wealth LLC purchased a new stake in shares of DexCom during the 4th quarter valued at about $43,000. Finally, Rothschild Investment LLC increased its position in shares of DexCom by 59.9% during the 3rd quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 245 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on DXCM. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Truist Financial reaffirmed a “buy” rating and set a $80.00 price target (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Monday, May 18th. Robert W. Baird set a $80.00 price target on shares of DexCom in a research report on Friday, May 1st. Finally, BTIG Research reaffirmed a “buy” rating and set a $85.00 price target on shares of DexCom in a research report on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.21.

Insider Activity at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the sale, the director directly owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. This represents a 3.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $59.91, for a total transaction of $101,847.00. Following the completion of the sale, the executive vice president directly owned 109,504 shares of the company’s stock, valued at $6,560,384.64. This represents a 1.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,112 shares of company stock valued at $379,990 over the last three months. 0.28% of the stock is currently owned by insiders.

DexCom Stock Performance

DexCom stock opened at $72.10 on Tuesday. The firm has a 50 day moving average of $63.72 and a 200 day moving average of $66.09. The firm has a market capitalization of $27.82 billion, a price-to-earnings ratio of 30.81, a P/E/G ratio of 1.19 and a beta of 1.40. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 EPS. As a group, research analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.